摘要
目的研究噻托溴铵联用舒利迭(50μg/250μg)治疗稳定期慢性阻塞性肺疾病(COPD)并冠心病(CHD)老年患者的疗效及安全性。方法 65名稳定期的中重度COPD并CHD老年患者随机分观察组33例,对照组32例,对照组吸入舒利迭(50μg/250μg),观察组联合应用噻托溴铵,在治疗前、治疗3月、6月后行肺功能、动态心电图及肝肾功能检测。结果治疗6月后观察组呼吸困难改善,总有效率(90.91%)明显高于对照组(71.88%),P<0.05。两组患者经治疗后肺功能有明显改善(P<0.01),而观察组联合治疗改善作用更显著。两组动态心电图比较差异无统计学意义(P>0.05)。结论舒利迭联合噻托溴铵治疗COPD并CHD老年患者可以明显改善呼吸困难症状及肺功能,安全性好。
Objective To study the efficacy and safety of combined inhaled tiotropium bromide and seretide（ 50μg/250μg）in the treatment of chronic obstructive pulmonary disease （COPD） in stable with coronary heart disease （CHD）. Method 65 patients of COPD in stable with coronary heart disease were divided into observation group （33 cases） and control group （32 cases）. The control group was given seretide （50μg/250μg）, observation group received the combination of tiotropium. Pulmonary function, dynamic elec- trocardiogram, liver and kideney function were made respectively before treatment, 3 months and 6 months after treatment. Result After 6 months, the observation group were effective in ameliorate dyspnea, and the total effective rate in observation group （90. 91% ） was sig- nificantly higher than that in control group （71.88 % ） with significant difference （ P 〈 0. 05 ）. After treatment, the pulmonary function in patients of both groups were obviously improved （P 〈0.01 ） , the improvement in observation group was more greater （P 〈0.01 ）. dDy- namie electrocardiogram were no significant differences in all patients. Conclusion Salmeterol and fluticasone propionate combined tiotro- plum can significantly improve the clinical symptoms in patients of COPD in stable with coronary heart disease with safety.
出处
《临床肺科杂志》
2012年第12期2174-2176,共3页
Journal of Clinical Pulmonary Medicine
